Ascletis Pharma Begins Phase I Study of Potential Psoriasis Treatment ASC50 in Healthy Participants Ascletis Pharma has initiated a Phase I clinical study of ASC50, an oral IL-17 inhibitor for psoriasis, showing promising safety and efficacy in early trials.

Ascletis Pharma Begins Phase I Study of Potential Psoriasis Treatment ASC50 in Healthy Participants #Hong_Kong #Ascletis_Pharma #ASC50 #Psoriasis_Treatment

Innovent Biologics Launches Phase 3 Study for Psoriasis Treatment with Picankibart Antibody Innovent Biologics has commenced a Phase 3 clinical trial for picankibart, targeting psoriasis patients with previous inadequate responses to treatments, aiming to improve treatment outcomes.

Innovent Biologics Launches Phase 3 Study for Psoriasis Treatment with Picankibart Antibody #China #Suzhou #Innovent_Biologics #Picankibart #Psoriasis_Treatment